"Product Profiles: Targeted Cancer Therapies - Patient Selection Driving Novel Drug Approvals" - New Market Report
The rising incidence of cancer is continuing to drive intense R&D interest in oncology. Drug developers are shifting their attention towards the development of novel therapies for molecularly defined patient populations. The future will increasingly see the approval of targeted therapies for specific molecular aberrations and the incorporation of companion diagnostics in routine clinical practice.
View full press release